Economic burden and quality of life impairment increase with severity of PD

Keränen, Tapani; Kaakkola, Seppo; Sotaniemi, K. A.; Laulumaa, Veikko; Haapaniemi, Tarja H.; Jolma, T; Kola, H; Ylikoski, Ari; Satomaa, O; Kovanen, J.; Taimela, Eeva; Haapaniemi, Helena; Turunen, Heidi; Takala, Aino K.

doi:10.1016/s1353-8020(02)00097-4

Cited by 143 publications

(123 citation statements)

References 24 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…28,29 Studies in Finland, Norway and the UK have shown an inverse correlation between HRQoL and PD severity and that disability, motor (decreased mobility, instability and falls) and non-motor symptoms (depression, fatigue, pain and cognition) directly affect HRQoL. [30][31][32] The impact of the disease was further emphasised in a study of 227 patients with PD: health and HRQoL, as determined using the SF-36 health survey, was substantially worse than in the general population. in a study on 434 consecutive PD patients who were assessed for non-motor symptoms.…”

Section: What Is Quality Of Life and What Scales Are Used In Parkinsomentioning

confidence: 99%

Quality of Life in Parkinson’s Disease – Patient, Clinical and Research Perspectives

Stocchi¹,

Martinez‐Martín

Reichmann

2014

European Neurological Review

View full text Add to dashboard Cite

Parkinson's disease (PD) has a severely negative impact on the quality of life (QoL) of patients and their caregivers. Health-related QoL (HRQoL) is a patient-reported component of QoL that includes physical, mental and social domains and in PD is an increasingly important part of patient monitoring. HRQoL in PD is assessed using a range of different generic (e.g. Short Form-36) and PD-specific (e.g. 39-item Parkinson's Disease Questionnaire) instruments/questionnaires. It is important that HRQoL is regularly determined in patients with PD to identify determinants of their HRQoL deterioration and appropriately manage them. The perspectives of PD patients, clinicians and researchers, however, can be different. In PD, motor symptoms such as slowness or tremor are the most visible manifestations of the disease and these tend to be concentrated on by doctors. PD patients, however, are likely to also have a range of non-motor symptoms such as nocturia, urinary frequency, fatigue, drooling and forgetfulness, which can be more troubling than motor symptoms. These can increase distress and social isolation but are often unreported or overlooked. In addition, morning akinesia and wearing-off phenomena may cause additional difficulty. However, these symptoms and patient concerns can be readily identified using simple HRQoL measures. The management of PD should therefore take into account patient, clinical and research perspectives of HRQoL in order to recognise and adequately address the consequences of motor and non-motor symptoms in PD.

show abstract

Section: What Is Quality Of Life and What Scales Are Used In Parkinsomentioning

confidence: 99%

Quality of Life in Parkinson’s Disease – Patient, Clinical and Research Perspectives

Stocchi¹,

Martinez‐Martín

Reichmann

2014

European Neurological Review

View full text Add to dashboard Cite

show abstract

“…Our model was based on the Swedish health care system, but devised to be applicable to available data on treatment costs and health state utilities for different HY stages. Such data are now available from a variety of countries (see, e.g., Refs 17,[27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement

Hjelmgren¹,

Ghatnekar²,

Reimer³

et al. 2006

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to €12 000-€64 000 according to cost-per-QALY thresholds of €38 000-€70 000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD.3

show abstract

“…Several studies have been performed to date in different countries to analyze the economic and social burden of PD. According to this literature, the main drivers of the total direct cost of PD are hospitalization and drug costs (Keranen et al, 2003;O'Brien et al, 2009) and the main drivers of total indirect cost are nursing care and productivity loss (Dengler et al, 2006;Hagell et al, 2002;O'Brien et al, 2009). In the United States, the annual economic impact of PD was estimated in 2007 at $10.78 billion, being 58% of this amount related to direct medical costs ($6.22 billion) (O'Brien et al, 2009).…”

Section: Economic Burden Of Parkinson Diseasementioning

confidence: 99%

Cost and Efficacy of Therapies for Advanced Parkinson's Disease

Valldeoriola¹

2011

Towards New Therapies for Parkinson's Disease

View full text Add to dashboard Cite

Economic burden and quality of life impairment increase with severity of PD

Cited by 143 publications

References 24 publications

Quality of Life in Parkinson’s Disease – Patient, Clinical and Research Perspectives

Quality of Life in Parkinson’s Disease – Patient, Clinical and Research Perspectives

Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement

Cost and Efficacy of Therapies for Advanced Parkinson's Disease

Contact Info

Product

Resources

About